☆ 4.2 Review

Antiangiogenic Therapy in Colorectal Cancer

CANCER JOURNAL (2018)

Journal

CANCER JOURNAL

Volume 24, Issue 4, Pages 165-170

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1097/PPO.0000000000000328

Keywords

Bevacizumab; cancer; colon; rectum; VEGF

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of patients with colorectal cancer will have metastatic disease at the time of initial diagnosis, and approximately 30% to 50% of patients with primary colon cancer will relapse and die of metastatic cancer. The 5-year survival rate of metastatic colorectal cancer remains disappointing at approximately 10%. Angiogenesis plays a significant role in tumor growth and metastasis in colorectal carcinoma. There are currently 4 US Food and Drug Administration-approved antiangiogenic agents for metastatic colorectal cancer. Bevacizumab is the only antiangiogenic agent approved by the US Food and Drug Administration for first-line treatment of metastatic colorectal cancer. Other antiangiogenic agents include ramucirumab, ziv-aflibercept, and regorafenib. We review the data supporting the use of antiangiogenics in this disease.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment

Meiling Yang, Ciqiu Yang, Dong Ma, Zijun Li, Wei Zhao, Dongyang Yang

Summary: The combination of FOLFOX and bevacizumab is a promising treatment for advanced colorectal cancer. The response of the tumor microenvironment to FOLFOX-Bev treatment was explored using single-cell transcriptomic analysis. The study found that cancer cells with specific characteristics respond better to FOLFOX-Bev treatment, and it also enhances the anti-tumor immune response.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Bevacizumab in advanced endometrial cancer

Maria M. Rubinstein, Shannan Dickinson, Priyanka Narayan, Qin Zhou, Alexia Iasonos, Weining Ma, Yulia Lakhman, Vicky Makker

Summary: The study reviewed the use of bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer, finding that it was associated with modest clinical efficacy and remains a viable palliative option in heavily pretreated patients.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Blocking CD47 Shows Superior Anti-tumor Therapeutic Effects of Bevacizumab in Gastric Cancer

Chenyang Shi, Jiaxin Li, Guorong Fan, Yu Liu

Summary: This study proposes a synergistic antitumour strategy by simultaneously blocking VEGF and CD47 signalling to enhance the therapeutic effect of bevacizumab on advanced gastric cancer. The results demonstrate that this strategy can reverse immune-related resistance, enhance antitumour effects, and inhibit tumour metastasis.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Oncology

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn L. Fleming, Jimmy Belotte, Erika K. Keeton, Ping Wang, Divya Gupta, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson

Summary: This study evaluated the safety and efficacy of Niraparib + bevacizumab as a first-line maintenance therapy for newly diagnosed advanced ovarian cancer patients. The results showed promising PFS outcomes and the safety profile was consistent with the monotherapy of these drugs.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano

Summary: This study investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer. The results showed promising efficacy and manageable toxicity of this treatment in the first-line setting.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Oncology

The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer

Domenico Ribatti, Antonio Giovanni Solimando, Francesco Pezzella

Summary: Several anti-angiogenic drugs are approved for cancer treatment, but resistance and adverse effects may occur. Combining multiple anti-angiogenic molecules or using them in combination with other treatment regimens is indicated as alternative therapeutic strategies to overcome resistance. Comprehensive omics profiling is crucial for increasing clinical benefits and overcoming resistance to anti-angiogenic therapies.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

Electrochemotherapy of Primary Colon Rectum Cancer and Local Recurrence: Case Report and Prospective Analysis

Daniela Rega, Vincenza Granata, Antonella Petrillo, Ugo Pace, Massimiliano Di Marzo, Roberta Fusco, Valeria D'Alessio, Guglielmo Nasti, Carmela Romano, Antonio Avallone, Vincenzo Ravo, Fabiana Tatangelo, Piera Maiolino, Raffaele Palaia, Francesco Izzo, Paolo Delrio

Summary: Electrochemotherapy (ECT) has shown effectiveness in treating deep solid tumors. Preliminary results in patients with locally advanced rectal cancer (LARC) treated with ECT demonstrated disease stabilization, pain reduction, and effective local control of recurrence.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Oncology

Cancer Stem Cells in Tumor Microenvironment of Adenocarcinoma of the Stomach, Colon, and Rectum

Jose Francisco Islas, Adriana G. Quiroz-Reyes, Paulina Delgado-Gonzalez, Hector Franco-Villarreal, Juan Luis Delgado-Gallegos, Elsa N. Garza-Trevino, Carlos A. Gonzalez-Villarreal

Summary: This article summarizes the relationship between gastrointestinal cancer stem cells and the microenvironment, as well as new targeted therapies for modulating cancer cells and the microenvironment. It is of great significance for the management of gastrointestinal cancer.

CANCERS (2022)

Add to Collection

Article Oncology

Competing Endogenous RNA in Colorectal Cancer: An Analysis for Colon, Rectum, and Rectosigmoid Junction

Lucas Maciel Vieira, Natasha Andressa Nogueira Jorge, Joao Batista de Sousa, Joao Carlos Setubal, Peter F. Stadler, Maria Emilia Machado Telles Walter

Summary: This study identified diagnostic and prognostic biomarkers for colon, rectum, and rectosigmoid junction cancer using ceRNA networks, highlighting differences in CRC behavior at different anatomical sites. The findings emphasize the importance of correctly identifying the tumor site.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Intramural cancer recurrence in the rectum after curative surgery for proximal sigmoid colon cancer: a case report

Yusuke Asada, Katsuya Chinen, Ken Yamataka, Jo Tokuyama, Naoto Kurihara, Shuhei Iida

Summary: This is a rare case of intramural recurrence in colorectal cancer, with distant metastasis in the rectum. PET-CT and short-interval repeat colonoscopy can improve detection of intramural recurrence. A long distal margin should be preserved during surgery to prevent recurrence.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells

Yuanchun Fan, Huimin Cheng, Yueping Liu, Shihao Liu, Scott Lowe, Yaru Li, Rachel Bentley, Bethany King, John Pocholo W. Tuason, Qin Zhou, Chenyu Sun, Hui Zhang

Summary: This study evaluated the effects of metformin and bevacizumab on ovarian cancer cell proliferation, tumor hypoxia, and tumor stem cells in vitro and in vivo. The results showed that the combination therapy significantly inhibited tumor growth, reduced the proportion of cancer stem cells, and improved tumor hypoxia in the microenvironment.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies

Menglu Zhang, Jiaqi Liu, Gang Liu, Zeyu Xing, Ziqi Jia, Jiaxin Li, Wenyan Wang, Jie Wang, Ling Qin, Xin Wang, Xiang Wang

Summary: Breast cancer, the highest incidence of female malignancy, is heavily reliant on neo-vascularization for growth and metastasis, with Vascular Endothelial Growth Factor (VEGF) playing a crucial role. This review focuses on the prognostic value of VEGF in breast cancer, clinical experiences with anti-VEGF therapeutics, and biomarkers for predicting the effectiveness of anti-angiogenic treatment.

CANCER LETTERS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Cancer of colon, rectum and anus: the rising burden of disease worldwide from 1990 to 2019

Milena Ilic, Irena Ilic

Summary: The incidence and mortality rates of CRA vary globally, with an increasing trend in incidence and a decreasing trend in mortality. The highest increase is observed in the East Asia and Andean Latin America regions. Of concern is the significant increase in incidence and mortality rates among individuals aged 15-49.

JOURNAL OF PUBLIC HEALTH (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Apoptosis induction in human lung and colon cancer cells via impeding VEGF signaling pathways

Maryam Farzaneh Behelgardi, Zahra Gholami Shahvir, S. Mohsen Asghari

Summary: This study assessed the effects of a VEGF antagonist peptide, VGB4, on human lung adenocarcinoma cells and human colon adenocarcinoma cells. The results showed that VGB4 effectively inhibited VEGF-induced cell proliferation and migration, and induced apoptosis in these cancer cells.

MOLECULAR BIOLOGY REPORTS (2022)

Add to Collection

Review Oncology

Taiwan Society of Colon and Rectum Surgeons (TSCRS) Consensus for Anti-Inflammatory Nutritional Intervention in Colorectal Cancer

Cheng-Jen Ma, Wan-Hsiang Hu, Meng-Chuan Huang, Jy-Ming Chiang, Pao-Shiu Hsieh, Huann-Sheng Wang, Chien-Ling Chiang, Hui-Min Hsieh, Chou-Chen Chen, Jaw-Yuan Wang

Summary: In patients with colorectal cancer, anti-inflammatory nutritional intervention is recommended to restore malnutrition and modulate systemic inflammatory response. Assessment of nutritional risk and systemic inflammatory response should be conducted before and after treatment, followed by appropriate nutritional and/or anti-inflammatory intervention.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study

Pedro L. S. Uson, Douglas Riegert-Johnson, Lisa Boardman, John Kisiel, Luke Mountjoy, Neej Patel, Blanca Lizaola-Mayo, Mitesh J. Borad, Daniel Ahn, Mohamad B. Sonbol, Jeremy Jones, Jonathan A. Leighton, Suryakanth Gurudu, Harminder Singh, Margaret Klint, Katie L. Kunze, Michael A. Golafshar, Ed D. Esplin, Robert L. Nussbaum, A. Keith Stewart, Tanio S. Bekaii-Saab, Niloy Jewel Samadder

Summary: Hereditary factors play a role in the development of colorectal cancer (CRC). This study found that 15.5% of CRC patients had pathogenic germline variants (PGVs), with only 16% of patients undergoing family variant testing. The research also showed that genetic testing results led to changes in treatment for 10% of patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Letter Oncology

Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data Reply

Mohamad Bassam Sonbol, Irbaz Bin Riaz, Tanios Bekaii-Saab

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

P. Grivas, A. R. Khaki, T. M. Wise-Draper, B. French, C. Hennessy, C-Y Hsu, Y. Shyr, X. Li, T. K. Choueiri, C. A. Painter, S. Peters, B. Rini, M. A. Thompson, S. Mishra, D. R. Rivera, J. D. Acoba, M. Z. Abidi, Z. Bakouny, B. Bashir, T. Bekaii-Saab, S. Berg, E. H. Bernicker, M. A. Bilen, P. Bindal, R. Bishnoi, N. Bouganim, D. W. Bowles, A. Cabal, P. F. Caimi, D. D. Chism, J. Crowell, C. Curran, A. Desai, B. Dixon, D. B. Doroshow, E. B. Durbin, A. Elkrief, D. Farmakiotis, A. Fazio, L. A. Fecher, D. B. Flora, C. R. Friese, J. Fu, S. M. Gadgeel, M. D. Galsky, D. M. Gill, M. J. Glover, S. Goyal, P. Grover, S. Gulati, S. Gupta, S. Halabi, T. R. Halfdanarson, B. Halmos, D. J. Hausrath, J. E. Hawley, E. Hsu, M. Huynh-Le, C. Hwang, C. Jani, A. Jayaraj, D. B. Johnson, A. Kasi, H. Khan, V. S. Koshkin, N. M. Kuderer, D. H. Kwon, P. E. Lammers, A. Li, A. Loaiza-Bonilla, C. A. Low, M. B. Lustberg, G. H. Lyman, R. R. McKay, C. McNair, H. Menon, R. A. Mesa, V Mico, D. Mundt, G. Nagaraj, E. S. Nakasone, J. Nakayama, A. Nizam, N. L. Nock, C. Park, J. M. Patel, K. G. Patel, P. Peddi, N. A. Pennell, A. J. Piper-Vallillo, M. Puc, D. Ravindranathan, M. E. Reeves, D. Y. Reuben, L. Rosenstein, R. P. Rosovsky, S. M. Rubinstein, M. Salazar, A. L. Schmidt, G. K. Schwartz, M. R. Shah, S. A. Shah, C. Shah, J. A. Shaya, S. R. K. Singh, M. Smits, K. E. Stockerl-Goldstein, D. G. Stover, M. Streckfuss, S. Subbiah, L. Tachiki, E. Tadesse, A. Thakkar, M. D. Tucker, A. K. Verma, D. C. Vinh, M. Weiss, J. T. Wu, E. Wulff-Burchfield, Z. Xie, P. P. Yu, T. Zhang, A. Y. Zhou, H. Zhu, L. Zubiri, D. P. Shah, J. L. Warner, GdL Lopes

Summary: This study analyzed clinical factors and laboratory measurements of cancer patients with COVID-19, finding that factors such as age, sex, comorbidities, cancer type, and laboratory results were associated with COVID-19 severity. Patients diagnosed early in the pandemic had worse outcomes, and specific anticancer therapies may increase 30-day all-cause mortality. More research is needed to confirm these findings and caution may be needed in using certain anticancer treatments.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186

Cameron J. Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert O'Neil, Tanios Bekaii-Saab, Anne Noonan, Christopher McQuinn, Thomas A. Mace, Walid Shaib, Christina Wu, Bassel F. El-Rayes, Safi Shahda, Gregory B. Lesinski

Summary: Modified FOLFOX6 combined with pembrolizumab showed promising results in treating metastatic colorectal cancer, with improved progression-free survival (PFS) and overall response rates. However, immune biomarkers associated with response were identified, while immunosuppressive myeloid and T cell subsets were not related to treatment outcomes. Further research is needed to explore the potential of combining chemotherapy with immune checkpoint inhibitors in future regimens.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study

Zev A. Wainberg, Tanios Bekaii-Saab, Patrick M. Boland, Farshid Dayyani, Teresa Macarulla, Kabir Mody, Bruce Belanger, Fiona Maxwell, Yan Moore, Arunthathi Thiagalingam, Tiffany Wang, Bin Zhang, Andrew Dean

Summary: The open-label, phase I/II study evaluated the safety and efficacy of first-line NALIRIFOX for patients with locally advanced/metastatic pancreatic ductal adenocarcinoma. The study found that NALIRIFOX was generally manageable and tolerable for patients, but some patients experienced severe treatment-related adverse events. MEDIAN PFS and OS were 9.2 and 12.6 months, respectively, indicating potential efficacy of NALIRIFOX in this patient population. A randomized, controlled phase III study is ongoing to further evaluate the treatment.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape

Kristen K. Ciombor, John H. Strickler, Tanios S. Bekaii-Saab, Rona Yaeger

Summary: BRAF-mutated advanced colorectal cancer is a critical subset with prognostic and predictive implications. Standard therapies include bevacizumab and encorafenib, but resistance to targeted treatment remains a challenge.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Adjuvant nab-Paclitaxel plus Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open -Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni

Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer

Tanios S. Bekaii-Saab, Sigrid Balser, Ragna Lohmann, Hasan Daoud, Bernd Liedert, Dorothee Schliephake

Summary: This study evaluates the safety and efficacy of BI 695502 in combination with chemotherapy for the treatment of mCRC. The results show that BI 695502 has acceptable safety and efficacy profiles, with a significant proportion of patients experiencing disease control. This study is of importance in guiding the treatment of mCRC.

COLORECTAL CANCER (2022)

Add to Collection

Article Oncology

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation

Tanios S. Bekaii-Saab, Rona Yaeger, Alexander I. Spira, Meredith S. Pelster, Joshua K. Sabari, Navid Hafez, Minal Barve, Karen Velastegui, Xiaohong Yan, Aditya Shetty, Hirak Der-Torossian, Shubham Pant

Summary: The study evaluated the clinical activity and safety of adagrasib in patients with other solid tumors harboring a KRAS(G12C) mutation. The results demonstrated encouraging clinical activity and good tolerability of adagrasib in this rare cohort of pretreated patients with KRAS(G12C)-mutated solid tumors.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem

Summary: In an open-label phase 3 study, it was found that the addition of napabucasin to nab-paclitaxel with gemcitabine did not improve efficacy in patients with previously untreated metastatic pancreatic adenocarcinoma (mPDAC). However, the safety profile of napabucasin was consistent with previous reports. This study reinforced the value of nab-paclitaxel plus gemcitabine as a platform for novel therapeutic approaches in mPDAC.

ECLINICALMEDICINE (2023)

Add to Collection

Review Oncology

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

Tanios S. Bekaii-Saab, Krzysztof Lach, Ling- Hsu, Muriel Siadak, Mike Stecher, James Ward, Rachel Beckerman, John H. Strickler

Summary: This review assesses the prognostic and predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes in patients with RAS wild-type metastatic colorectal cancer. The results suggest that HER2-positive patients have worse progression-free survival and overall response rate with anti-EGFR therapy, emphasizing the importance of HER2 testing in treatment decision-making and optimizing outcomes.

ONCOLOGIST (2023)

Add to Collection

Review Gastroenterology & Hepatology

Frontline therapy for advanced hepatocellular carcinoma: an update

Mehmet Akce, Bassel F. El-Rayes, Tanios S. Bekaii-Saab

Summary: Hepatocellular carcinoma (HCC) is rapidly becoming a leading cause of cancer-related mortality in the US. Current frontline systemic therapy options include sorafenib, lenvatinib, and atezolizumab/bevacizumab. The landscape of frontline HCC treatment is changing rapidly.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements

Daniel Walden, Cody Eslinger, Tanios Bekaii-Saab

Summary: Biliary tract cancers, a diverse and aggressive malignancy, have a poor prognosis and limited treatment options. However, advancements in genetic sequencing have opened up new avenues for targeted therapy in this field.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes

Grant Wintheiser, Tyler Zemla, Qian Shi, Nguyen Tran, Kritika Prasai, Sri Harsha Tella, Kabir Mody, Daniel Ahn, Mitesh Borad, Tanios Bekaii-Saab, Amit Mahipal

Summary: This study characterized the clinical features and prognosis of patients with isocitrate dehydrogenase (IDH)-mutant intrahepatic cholangiocarcinoma (CCA). The study found that patients with mIDH had better survival compared to other subtypes. First-line chemotherapy regimens containing gemcitabine showed higher disease control rate and overall response rate. IDH inhibitors were a promising therapeutic option in later lines of therapy in this subgroup.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Frontline therapy for advanced hepatocellular carcinoma: an update

Mehmet Akce, Bassel F. El-Rayes, Tanios S. Bekaii-Saab

Summary: Hepatocellular carcinoma is the fastest-growing cause of cancer-related mortality in the US and is projected to be the third leading cause by 2030. Main risk factors include alcoholic cirrhosis, chronic hepatitis B, hepatitis C, and nonalcoholic steatohepatitis. Approved frontline systemic therapy options include sorafenib, lenvatinib, and atezolizumab/bevacizumab. The landscape of frontline HCC treatment is rapidly changing.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.